New Anticoagulation Strategies of VV-ECMO

Status Withdrawn

Clinical Trial Summary

Effective and normative anticoagulation is one of the most important components of Extracorporeal membrane oxygenation (ECMO) management. Excessive anticoagulation may lead to hemorrhage, which is the most common and serious complication. Currently, the most common factors for monitoring anticoagulation of ECMO are the activated clotting time (ACT) and activated partial thromboplastin time (APTT). However, there is a lack of a unified understanding of the related monitoring measures, monitoring targets, and bleeding risk assessments, which have been chosen mainly because of experiences reported by various ECMO centers or the results of retrospective studies.Therefore, anticoagulation strategies need to be improved. Our research have found ECMO anticoagulation management should be transformed from monitoring only the APTT/activated clotting time (ACT) to considering the entire coagulation process. To maintain thrombosis ability and PLT function within normal ranges may help reduce hemorrhage rates and improve prognoses. This randomized controlled study aim to develop the safety and efficacy new anticoagulation strategies of VV-ECMO.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hemorrhage

Clinical Trial Details

NCT number	NCT03497338
Study type	Observational [Patient Registry]
Source	Beijing Chao Yang Hospital
Contact
Status	Withdrawn
Phase
Start date	April 1, 2018
Completion date	March 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02815670` - Reversal Dabigatran Anticoagulant Effect With Idarucizumab	Phase 3
Completed	`NCT04588350` - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery	N/A
Recruiting	`NCT02972385` - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed	`NCT02554006` - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings	N/A
Completed	`NCT02569606` - Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
Recruiting	`NCT02446730` - Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome	Phase 4
Completed	`NCT01955720` - Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran	Phase 1
Completed	`NCT01935427` - Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume	N/A
Recruiting	`NCT01709786` - Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage	N/A
Completed	`NCT01136590` - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery	Phase 4
Completed	`NCT01210417` - Trauma Heart to Arm Time	N/A
Completed	`NCT01191554` - Dose-ranging Study of Tranexamic Acid in Valve Surgery	N/A
Completed	`NCT01085006` - The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery	Phase 1/Phase 2
Completed	`NCT00700141` - Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®	N/A
Completed	`NCT00375466` - Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.	N/A
Completed	`NCT00147420` - RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet	N/A
Completed	`NCT00479362` - Anticoagulant Therapy During Pacemaker Implantation	Phase 4
Recruiting	`NCT05945680` - Tranexamic Acid in Breast Esthetic Surgery.	Phase 4
Completed	`NCT03273322` - Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure	Phase 2/Phase 3
Withdrawn	`NCT05672407` - The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery	Phase 4